Skip to main content
CANbridge Pharmaceuticals Inc. logo

CANbridge Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · 1228 LEI · 8755009KKZM9ETBOF853 HKEX Manufacturing
Open in API
Filings indexed 190 across all filing types
Latest filing 2026-02-20 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1228

About CANbridge Pharmaceuticals Inc.

http://www.canbridgepharma.com

CANbridge Pharmaceuticals Inc. is a global biopharmaceutical company focused on the research, development, and commercialization of transformative therapies for rare diseases and rare genetic conditions. The company leverages its foundation in China to deliver life-changing therapeutics globally. Its commercial portfolio includes approved products such as Hunterase® (a recombinant human Enzyme Replacement Therapy) and Livmarli (an oral inhibitor of the ileal bile acid transporter). CANbridge also maintains a pipeline of investigational therapies, including gene therapies, targeting high-impact indications in rare genetic diseases.

Recent filings

Filing Released Lang Actions
SUPPLEMENTAL ANNOUNCEMENT REGARDING THE GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS
Regulatory Filings Classification · 1% confidence The document is a supplemental announcement regarding the grant of share options and restricted share units (RSUs) to service providers. It provides additional context to a previous announcement dated January 12, 2026. Since this document relates to the issuance of equity-based compensation and capital-related instruments (share options/RSUs) and does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Remuneration' (which is for executive compensation disclosures), it falls under the general regulatory announcement category for capital changes or corporate actions.
2026-02-20 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2026
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' filed with the Hong Kong Exchanges and Clearing Limited. This is a standard regulatory filing required by the HKEX for listed companies to report monthly movements in securities, including share capital, share options, and issued shares. It does not fit into specific categories like 'Annual Report' or 'Earnings Release' but is a mandatory regulatory disclosure regarding capital structure changes. Therefore, it is classified as a Regulatory Filing (RNS).
2026-02-05 English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS
Share Issue/Capital Change Classification · 1% confidence The document is an official announcement from CANbridge Pharmaceuticals Inc. regarding the 'Grant of Share Options and Restricted Share Units' to directors, employees, and service providers. It details the number of options/RSUs, vesting schedules, exercise prices, and compliance with the Hong Kong Stock Exchange Listing Rules. This type of disclosure regarding equity-based compensation and capital changes is classified as a regulatory filing concerning share issuance and capital structure changes.
2026-01-12 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2025
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in their share capital, including share options, warrants, and other equity-related changes. Since it details changes in share capital and issued shares, it falls under the category of share issues and capital changes.
2026-01-07 English
VOLUNTARY ANNOUNCEMENT
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement issued by CANbridge Pharmaceuticals Inc. regarding the inclusion of their drug, CAN 103, in China's 'Commercial Health Insurance Innovative Drug List'. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement (RPA) as it provides substantive news rather than just announcing the availability of a report. Since it is a general corporate announcement regarding business operations and regulatory milestones that does not fall into the other specialized categories, it is best classified as a Regulatory Filing (RNS).
2025-12-08 English
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON DECEMBER 4, 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING' and details the voting outcomes for specific resolutions presented at an EGM held on December 4, 2025. It includes a table of votes for and against the resolutions and confirms the passage of these resolutions. This aligns perfectly with the definition for 'Declaration of Voting Results & Voting Rights Announcements'.
2025-12-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.